After Mizuho Securities and SunTrust Robinson gave Supernus Pharmaceuticals (NASDAQ: SUPN) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Matthew Lillis maintained a Buy rating on Supernus Pharmaceuticals today and set a price target of $57. The company’s shares opened today at $35.40, close to its 52-week low of $34.90.
Lillis noted:
“We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets the bipolar indication opportunity for Oxtellar XR. $57 price target is based on DCF and SOP analyses that forecast peak Oxtellar XR and Trokendi XR sales of $170 million (by 2026) and $450 million (2021).”
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $59.50 average price target, implying a 68.1% upside from current levels. In a report issued on November 30, Cowen & Co. also assigned a Buy rating to the stock with a $55 price target.
.
See today’s analyst top recommended stocks >>
Supernus Pharmaceuticals’ market cap is currently $1.86B and has a P/E ratio of 19.39. The company has a Price to Book ratio of 4.41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
